References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organiza-tion classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20):2391–405.
NCCN Guidelines Version 1.2020-August 27, 2019. Myelo-dysplastic Syndromes. http://medi-guide.meditool.cn/
ymtpdf/A1721A1C-DA35-3F68-122A-3429A1F100BF.pdf
Marisavljević D, Rolović Z, Sefer D, Basara N, Ilić D, Bosković D, Colović M. Biological and clinical significance of clonogenic as-says in patients with myelodysplastic syndromes. Med Oncol 2002; 19(4): 249–59.
Kohlmann A, Bacher U, Schnittger S, Haferlach T. Perspective on how to approach molecular diagnostics in acute myeloid leu-kemia and myelodysplastic syndromes in the era of next-generation sequencing. Leuk Lymphoma 2014; 55: 1725–34.
Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 2013; 92: 19–24.